Bevacizumab - Genentech/Roche

Drug Profile

Bevacizumab - Genentech/Roche

Alternative Names: Avastin; RG-435; rhuMAb-VEGF; RO-4876646

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech; Hackensack University Medical Center
  • Developer All Ireland Cooperative Oncology Research Group; Austrian Breast & Colorectal Cancer Study Group; Bayer; Beth Israel Deaconess Medical Center; Breast Cancer Research Foundation; Brigham and Women's Hospital; Bristol-Myers Squibb; Cancer and Leukemia Group B; Cancer Research UK; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Duke University; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; Genentech; Hackensack University Medical Center; Hoosier Cancer Research Network; Indiana University School of Medicine; Japan Breast Cancer Research Group; Massachusetts General Hospital; Medical University of South Carolina; Melanoma Research Foundation Breakthrough Consortium; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National Comprehensive Cancer Network; NCIC Clinical Trials Group; North Central Cancer Treatment Group; NSABP Foundation; Ohio State University Medical Center; Peter MacCallum Cancer Centre; Roche; Royal Marsden NHS Foundation Trust; Sanofi; Sarcoma Alliance for Research through Collaboration; SCRI Development Innovations; South Eastern European Research Oncology Group; Spanish Cooperative Group for Digestive Tumour Therapy; Spanish Lung Cancer Group; Stanford University School of Medicine; SWOG; The Catalan Institute of Oncology; UNICANCER; University College London; University of Alabama at Birmingham; University of Arkansas System; University of California, Davis; University of Iowa; University of Tennessee; University of Texas M. D. Anderson Cancer Center; US Oncology Research; West German Study Group; Xijing Hospital
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Pancreatic cancer; Renal cell carcinoma; Mesothelioma; Cervical cancer; Ovarian cancer; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Cervical cancer; Colorectal cancer; Glioblastoma; Glioma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
  • Phase III Head and neck cancer
  • Phase II Brain metastases; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Hepatocellular carcinoma; Hodgkin's disease; Liver cancer; Liver metastases; Malignant melanoma; Meningioma; Multiple myeloma; Neuroblastoma; Neurofibromatoses; Peritoneal cancer; Rectal cancer; Soft tissue sarcoma; Urogenital cancer
  • Phase I/II Neoplastic meningitis; Sarcoma
  • Phase I Solid tumours
  • Suspended Carcinoid tumour
  • Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Eye-Disorders; Gastric cancer; Gastrointestinal stromal tumours; Mesothelioma; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer

Most Recent Events

  • 13 Feb 2018 Servier initiates enrolment in the phase III SOLSTICE trial for Colorectal cancer (Metastatic disease, Combination therapy, First-line therapy) in Austria (EudraCT2017-004059-22)
  • 05 Dec 2017 US FDA grants full approval for Glioblastoma (Second-line therapy or greater)
  • 05 Dec 2017 Efficacy and adverse events data from a phase III trial in Glioblastoma released by Genentech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top